The drugmakers said on Friday the Phase 3 trial showed the vaccine elicited a robust influenza A immune response, compared to a standard flu vaccine, but showed weaker results against the influenza B strain. The formulation showed similar responses against SARS-CoV-2 as the companies' COVID-19 vaccine.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/GNs6ct4
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment